Improving the understanding of originator and biosimilar biologics among healthcare providers in Saudi Arabia

• Автори: Mohammed A. Omair (Автор), Tariq Alhawassi (Автор), Munira Alwaihibi (Автор), Ghada Aldrees (Автор), Mahmoud Mosli (Автор), Wesam M. Asser (Автор), Maryam A. Alharaibi (Автор), Atheer T. Alotaibi (Автор), Doaa A. Bintaleb (Автор), Najah K. Alharbi (Автор), Ahmed Z. Alotaibi (Автор), Wajed A. Alshammari (Автор), Nouf Alanazi (Автор), Ali M. Asiri (Автор), Rana Almadany (Автор), Hanan Al Rayes (Автор), Turki Al-Thunian (Автор), Moureq Alotaibi (Автор), Abdulrazaq Al Jazaeri (Автор)
• Формат: Книга
• Опубліковано: Elsevier, 2020-12-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

The loss of patentability of many originator biologics has led to the rapid introduction of biosimilar agents. The anticipated economic benefit of introducing such agent has been accompanied by vagueness surrounding their biotechnology, approval requirements, positioning in treatment paradigms and p...